Phase 1 Study Cites Needle-Free Delivery Advantages

Invectys DNA Vaccine for Advanced Solid Tumors using PharmaJet Needle free injector reported safe for humans

cells

A Colorado-based maker of needle-free injection technology announced the results of the Invectys Phase I clinical trial of the delivery of the therapeutic cancer vaccine, INVAC-1.

Announced by PharmaJet on January 8, 2020, this is the first-in-human study of INVAC-1, an immune-therapeutic DNA vaccine for the treatment of cancer, which highlights the benefits of needle-free injection.

 INVAC-1 is a human telomerase DNA-based anti-cancer vaccine.

INVAC-1 vaccination was found safe, well-tolerated, and immunogenic when administered intradermally at the three tested doses in patients with relapsed or refractory cancers. Disease stabilization was observed for the majority of patients (58%) during the treatment period and beyond.

The INVAC-1 vaccine was delivered to patients either by intradermal injection followed by electroporation, or by intradermal needle-free injection using the PharmaJet Tropis® device. 

The new publication cites that ‘administration with Tropis is immunogenic and able to elicit hTERT specific CD4 and CD8 immune responses in patients.’ 

This represents a great improvement for patient care as administration by Tropis is easy to perform, reliable and precise. Moreover, this system is cost-effective and brings increased comfort for patients with lower pain and better local tolerance (compared to electroporation, said the Company.

Invectys has chosen the PharmaJet Tropis for its ongoing Phase II study for Chronic Lymphocytic Leukemia in the US and Europe, in addition to solid tumor studies in 2020. 

Sponsored Links:

“We are pleased with the continued success of PharmaJet Tropis in clinical studies with nucleic acid (DNA or RNA) vaccine delivery and look forward to its ongoing use in future studies, ” said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.

This is important news since the global burden of cancer is set to increase by more than 60% by 2040, to a predicted 29.4 million cases.

The INVAC-1 vaccine aims at mobilizing the immune system against the human telomerase complex (named hTERT), which is overexpressed in 90 percent of human tumors but is virtually absent from normal cells. 

The INVAC-1 vaccine activates CD8+ Cytotoxic T cells, also called killer T cells, which are capable of killing cancer cells. It also turns on CD4+ T helper cells, which regulate the immune response and stimulate the cytotoxic T cells.

PharmaJet’s mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. Visit PharmaJet for more information.

Cancer vaccine news published by Vax-Before-Cancer